Literature DB >> 22370328

Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.

Andres Jerez1, Lukasz P Gondek, Anna M Jankowska, Hideki Makishima, Bartlomiej Przychodzen, Ramon V Tiu, Christine L O'Keefe, Azim M Mohamedali, Denise Batista, Mikkael A Sekeres, Michael A McDevitt, Ghulam J Mufti, Jaroslaw P Maciejewski.   

Abstract

PURPOSE: Interstitial deletions of chromosome 5q are common in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), pointing toward the pathogenic role of this region in disease phenotype and clonal evolution. The higher level of resolution of single-nucleotide polymorphism array (SNP-A) karyotyping may be used to find cryptic abnormalities and to precisely define the topographic features of the genomic lesions, allowing for more accurate clinical correlations. PATIENTS AND METHODS: We analyzed high-density SNP-A karyotyping at diagnosis for a cohort of 1,155 clinically well-annotated patients with malignant myeloid disorders. results: We identified chromosome 5q deletions in 142 (12%) of 1,155 patients and uniparental disomy segments (UPD) in four (0.35%) of 1,155 patients. Patients with deletions involving the centromeric and telomeric extremes of 5q have a more aggressive disease phenotype and additional chromosomal lesions. Lesions not involving the centromeric or telomeric extremes of 5q are not exclusive to 5q- syndrome but can be associated with other less aggressive forms of MDS. In addition, larger 5q deletions are associated with either del(17p) or UPD17p. In 31 of 33 patients with del(5q) AML, either a deletion involving the centromeric and/or telomeric regions or heterozygous mutations in NPM1 or MAML1 located in 5q35 were present.
CONCLUSION: Our results suggest that the extent of the affected region on 5q determines clinical characteristics that can be further modified by heterozygous mutations present in the telomeric extreme.

Entities:  

Mesh:

Year:  2012        PMID: 22370328      PMCID: PMC3341146          DOI: 10.1200/JCO.2011.36.1824

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  30 in total

1.  The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2.

Authors:  M Uesugi; G L Verdine
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.

Authors:  Jacqueline Boultwood; Carrie Fidler; Amanda J Strickson; Fiona Watkins; Susana Gama; Lyndal Kearney; Sabrina Tosi; Arek Kasprzyk; Jan-Fang Cheng; Rina J Jaju; James S Wainscoat
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

3.  Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms.

Authors:  P D Castro; J C Liang; L Nagarajan
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

4.  Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).

Authors:  F Lai; L A Godley; J Joslin; A A Fernald; J Liu; R Espinosa; N Zhao; L Pamintuan; B G Till; R A Larson; Z Qian; M M Le Beau
Journal:  Genomics       Date:  2001-01-15       Impact factor: 5.736

5.  Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs.

Authors:  J Boultwood; C Fidler; A J Strickson; F Watkins; M Kostrzewa; R J Jaju; U Müller; J S Wainscoat
Journal:  Genomics       Date:  2000-05-15       Impact factor: 5.736

6.  NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).

Authors:  Carrie Fidler; Fiona Watkins; David T Bowen; Timothy J Littlewood; James S Wainscoat; Jacqueline Boultwood
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

7.  Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease.

Authors:  Cristine Alves da Costa; Eliezer Masliah; Frédéric Checler
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

8.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Authors:  John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

9.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.

Authors:  A A N Giagounidis; U Germing; S Haase; B Hildebrandt; B Schlegelberger; C Schoch; L Wilkens; M Heinsch; H Willems; M Aivado; C Aul
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

10.  A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.

Authors:  Apostolos Klinakis; Camille Lobry; Omar Abdel-Wahab; Philmo Oh; Hiroshi Haeno; Silvia Buonamici; Inge van De Walle; Severine Cathelin; Thomas Trimarchi; Elisa Araldi; Cynthia Liu; Sherif Ibrahim; Miroslav Beran; Jiri Zavadil; Argiris Efstratiadis; Tom Taghon; Franziska Michor; Ross L Levine; Iannis Aifantis
Journal:  Nature       Date:  2011-05-12       Impact factor: 49.962

View more
  53 in total

1.  What lies beyond del(5q) in myelodysplastic syndrome?

Authors:  Vera Adema; Rafael Bejar
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

2.  Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature.

Authors:  Anup Kasi Loknath Kumar; Brandon Weckbaugh; Christopher Sirridge; Janet Woodroof; Diane Persons; Suman Kambhampati
Journal:  Stem Cell Investig       Date:  2016-02-23

3.  Novel germline missense DDX41 variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia.

Authors:  Filippo Pinto E Vairo; Alejandro Ferrer; Elizabeth Cathcart-Rake; Rebecca L King; Matthew T Howard; David S Viswanatha; Eric W Klee; Abhishek A Mangaonkar; Mrinal M Patnaik
Journal:  Leuk Lymphoma       Date:  2018-11-08

4.  Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome.

Authors:  M E Varney; K Choi; L Bolanos; S Christie; J Fang; H L Grimes; J P Maciejewski; J-I Inoue; D T Starczynowski
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

Review 5.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

Review 6.  Genetics of MDS.

Authors:  Seishi Ogawa
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

7.  Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model.

Authors:  Angela Stoddart; Jianghong Wang; Chunmei Hu; Anthony A Fernald; Elizabeth M Davis; Jason X Cheng; Michelle M Le Beau
Journal:  Blood       Date:  2017-03-27       Impact factor: 22.113

8.  Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization.

Authors:  Meenakshi Mehrotra; Rajyalakshmi Luthra; Farhad Ravandi; Rachel L Sargent; Bedia A Barkoh; Ronald Abraham; Bal Mukund Mishra; L Jeffrey Medeiros; Keyur P Patel
Journal:  Leuk Lymphoma       Date:  2014-11

Review 9.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 10.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.